A series of bifunctional compounds with galactosyl residues as targeting ligand for asialoglycoprotein receptors on hepatocytes and various dendrimers as the DNA-binding domain was synthesized. When mixed with plasmid DNA, these compounds self assembled into particles that exhibited high transfection activity both in vitro and in vivo. Optimal activity in liver cells was observed with compounds containing three galactosyl residues and 16 dendrimer arms. These results suggest that domain-based design is an effective strategy for development of a new generation of synthetic gene carriers.
Many synthetic compounds have been evaluated as potential carriers for gene delivery. These include various cationic lipids, [1] [2] [3] different forms of polyethyleneimine (PEI), [4] [5] [6] [7] [8] [9] modified polylysine, 10,11 dendrimers, [12] [13] [14] chitosan, [15] [16] [17] [18] block copolymers, [19] [20] [21] and cyclodextrincontaining polycations. 22, 23 The predominant role of these synthetic or naturally occurring compounds is to form nuclease-resistant complexes with DNA that can be effectively endocytosed by a cell. The delivery efficiency of these gene carriers varies depending on their chemical structure, target cell type and excipients included in the formulation.
The major advantages of the synthetic vectors developed previously are their simplicity and effectiveness in mediating in vitro gene transfer into cells. The remaining challenge, however, is to develop carriers capable of mediating target-specific in vivo gene delivery for gene therapy. Toward this end, we synthesized a series of bifunctional compounds and assessed their in vitro and in vivo gene delivery activity. All of these compounds contain target-binding and DNA-binding domains that are joined together by the same separating linker. We reasoned that on mixing these compounds with DNA, the DNA-binding domain would bind with DNA while exposing the target-binding domain on the surface of the resulting complex. DNA should be encapsulated within the complex and be protected against nuclease-mediated degradation, whereas the exposed target-binding domains are able to bind to and deliver genes into the target cells.
To test this hypothesis, we elected to employ galactosyl residues as the targeting ligand for asialoglycoprotein receptors on hepatocytes and dendrimer arms as DNAbinding domain. As shown in Figure 1 , a series of bifunctional compounds was synthesized to optimize the structure of target-and DNA-binding domains, and to establish a structure-function relationship. The effect of the number of galactosyl residues on transfection was studied by preparing compounds with one, two or three galactosyl residues and an eight-arm dendrimer. To study the effect of the DNA-binding domain on transfection, compounds with 8-32 dendrimer arms were prepared. The structures of the synthesized compounds were confirmed by 1 H-and 13 C-NMR according to a previously established procedure 24 and named based on the number of galactosyl residues and dendrimer arms in each compound. For example, TriGal-Arm 16 represents a bifunctional compound containing three galactosyl residues and a dendrimer with 16 arms.
The transfection activity of the prepared compounds was first assessed in human hepatoma HepG2 cells that overexpress asialoglycoprotein receptors. 25 Using a luciferase gene in pCMV-Luc plasmid as a reporter, in vitro transfection was performed employing a fixed ratio of 2.5 of the terminal amino groups of the bifunctional compound to the phosphate groups of plasmid DNA (N/P ratio). Results given in Figure 2a demonstrate that luciferase gene expression increases as the number of galactosyl residues is increased. A 80-fold increase in luciferase expression in cells transfected with TriGal-Arm 8 over that in cells transfected with MonoGal-Arm 8 indicates the increased effectiveness of three galactosyl residues. Data in Figure 2b show a 100-fold increase in transfection activity of TriGal-Arm 16 and TriGal-Arm 32 over that of TriGal-Arm 8, suggesting that more than eight dendrimer arms are required for the DNA-binding domain. As expected and demonstrated in Figure 2b , free dendrimers were also TriGal-Arm 16 Figure 1 Bifunctional compounds employed in the study. Bifunctional compounds were synthesized according to the previously published procedures. 24 All synthetic compounds were purified by column chromatography and their structures confirmed by 1 H-and 13 C-NMR.
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Dendrimer TriGal-Dendrimer a b Figure 2 Structure-activity relationships of bifunctional compounds in HepG2 cells. Bifunctional compounds containing one (Mono-Gal), two (Di-Gal) or three (Tri-Gal) galactosyl residues and eight-arm dendrimers (a), or those containing three galactosyl residues and 8-, 16-or 32-arm dendrimer (b) in 125 ml of serum-free medium were mixed with an equal volume of pCMV-Luc plasmid DNA (1 mg) for an N/P ratio of 2.5. The mixture was incubated for 10 min at room temperature and then added to each well of HepG2 cells (1 Â 10 5 cells/well pre-seeded 24 h earlier in a 48-well plate). Transfection was allowed to proceed for 5 h and sufficient fetal bovine serum to adjust the serum concentration to 10% was added to each well. The transfection medium was replaced with fresh medium 19 h later and the cells were harvested 24 h after the medium change. Cell lysates were prepared by addition of lysis buffer (0.1 M Tris-HCl, 0.1% Triton X-100, 2 mM EDTA, pH 7.8) (100 ml/ well) followed by centrifugation for 10 min at 12 000 r.p.m. at 41C. The protein concentration of the supernatant was determined using a BioRad protein assay kit (Bio-Rad, Hercules, CA, USA). The level of luciferase gene expression in each well was determined using 10 ml of supernatant and a luciferase assay kit (Promega, Madison, WI, USA). Bifunctional compounds for targeted hepatic gene delivery KS Kim et al active in transfection albeit at a much lower level of activity. Together, these results demonstrate that chemical structure of both the DNA binding and the targeting domains of these bifunctional compounds are critical for efficient gene delivery.
On the basis of the above results, TriGal-Arm 16 was selected for further studies. Data given in Figure 3a show the effect of the N/P ratio on average particle size of complexes as analyzed by the method of laser light scattering. The effect of freeze-thaw on complex size was also studied. In absence of freeze-thaw, the average complex size increased from around 100 nm at a 0.5 N/P ratio to approximately 300 nm when the ratio was 6. Interestingly, three freeze-thaw cycles of the preformed complexes resulted in relatively constant particle size of 100-150 nm at all N/P ratios tested except for complexes with an N/P ratio of 1. Additional experiments using different buffer systems, 5% dextrose solution or distilled water with or without freeze-thaw cycles did not generate particles smaller that 100-150 nm at the N/P ratios employed (data not shown). These results suggest that freeze-thaw cycles promote formation of tighter complexes.
The structures of freeze-thawed complexes at N/P ratio of 4 were determined by electron microscopy. Figure 3b shows rather homogeneous particle size of the complexes under uranyl acetate or phosphotungstic acid staining. The average particle size (20-50 nm) seen in the EM appeared smaller than that measured by light scattering, suggesting the presence of small aggregates in samples subjected to light scattering measurements.
Transfection activities of complexes prepared at different N/P ratios are shown in Figure 3c . Complexes subjected to freeze-thaw were generally more active than those prepared by simple mixing. Complexes with N/P ratios of 4 or higher were more active in transfection than those with lower N/P ratios. These results suggest that both the N/P ratio and the method of complex prepa- Figure 3 Effect of N/P ratio and freeze-thaw on particle size (a) and morphology (b) of DNA/compound complexes, and transfection activity in mice (c). Various amounts of TriGal-Arm 16 in 200 ml saline were mixed with 50 mg pCMV-Luc plasmid DNA in 200 ml saline at the desired N/P ratio. The mixture was gently mixed and incubated at room temperature for 15 min before particle size measurement by laser light scattering in a Coulter B4 Plus Particle Analyzer (Beckman Coulter, Inc., Fullerton, CA, USA). For preparations involving freeze-thaw, the mixture was treated with three freeze-thaw cycles of 3 min on dry ice and 2 min at 401C after initial mixing. Samples were gently mixed after each cycle and incubated at room temperature for 15 min before size measurement. For electron microscopy, complexes with N/P ratio of 4 were prepared by freeze-thaw and subjected negative staining with either 1% uranyl acetate (UC) or phosphotungstic acid (PTA). Liver-specific gene delivery of TriGal-Arm 16 was evaluated in mice using complexes with an N/P ratio of 4. Mice were injected via the tail vein with complexes containing 50 mg of pCMV-Luc plasmid DNA and luciferase gene expression in the heart, lung, spleen, kidneys and liver measured 8 h later. Results given in Figure 4a show that among the organs examined, the liver is the only organ exhibiting luciferase gene expression. Figure 4a also shows that free Arm 16 dendrimers are not active in gene delivery. These results provide direct evidence in support of liver-specific gene delivery by TriGal-Arm 16, potentially mediated by asiaologlycoprotein receptors.
PTA Staining
To confirm that liver-specific gene delivery shown in Figure 4a is indeed mediated by asiaologlycoprotein receptors, we injected mice with asialofetuin (a natural ligand for asiaologlycoprotein receptors 25 ) via the tail vein before injection of DNA/TriGal-Arm 16 complexes. Figure 4b shows the dose-dependent effect of asialofetuin on the level of luciferase gene expression in mouse liver. Compared to control mice, the level of luciferase activity decreased about 100-fold on injection of 10 ng of asialofetuin per mouse and at 100 mg, decreased 10 000-fold. These experiments confirm that hepatic gene delivery by TriGal-Arm 16 is mediated by asialoglycoprotein receptors.
To establish a DNA dose-response curve, mice were injected with bifunctional compound complexes (N/P ratio of 4) containing 25-100 mg of plasmid DNA. As is evident in Figure 5 , the maximum level of luciferase gene expression occurred at 50 mg of plasmid DNA per animal and further increases in the total amount of plasmid DNA per mouse did not result in a further increase in reporter gene expression. Although relatively low compared to the level of reporter gene expression resulting from hydrodynamic gene delivery, 26, 27 the level of luciferase gene expression demonstrated here is among the highest ever achieved by intravenous transfection of the liver by a synthetic vector without hydrodynamic involvement.
In summary, development of safe and efficient carriers for target-specific gene delivery is the ultimate goal for many gene therapy studies. Toward this end, the results presented here demonstrate that structure-based design can be used as a new strategy for development of improved synthetic vectors. Separating the target-binding domain from the DNA-binding domain in vector design may prove more effective in designing molecules for optimized gene delivery efficiency than the commonly used trial-in-error approach that often requires testing of large numbers of compounds. With respect to liver-specific gene delivery targeting asialoglycoprotein receptors, data shown in Figures 3b, 4 and 5 provide direct evidence in support of the use of galactosyl residues as the targeting ligand for hepatic gene delivery. Future studies should investigate the optimal configu- 1.0E+03
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1.0E+06 25 50 75 100 DNA Amount (µg/mouse) Luciferase Activity (RLU/mg) Figure 5 Effect of DNA dose on the level of luciferase gene expression in mouse liver. Different amounts of plasmid DNA/ compound complexes at an N/P ratio of 4 in 400 ml of saline prepared by the freeze-thaw procedure were injected via the tail vein into CD-1 mice. The remaining experimental procedure was identical to that described in Figure 4 legend. Data represent the mean7s.d. from three separate experiments.
Bifunctional compounds for targeted hepatic gene delivery KS Kim et al ration of the trigalactosyl residues for efficient target binding. Similarly, different structural elements in the DNA-binding domain should also be explored for their ability to optimally condense DNA. From the standpoint of gene delivery, the results presented here represent an important step toward the rational design of more desirable gene carriers capable of condensing DNA and mediating efficient target-specific in vivo gene delivery.
